A2.31 Braf (v raf murine sarcoma viral oncogene homologue B1) mutations in rheumatoid arthritis patients

2015 ◽  
Vol 74 (Suppl 1) ◽  
pp. A28.2-A29
Author(s):  
F Arnoux ◽  
N Lambert ◽  
F Fina ◽  
M Martin ◽  
S Kanaan ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

A1.47 BRAF (v raf murine sarcoma viral oncogene homologue B1) mutations in rheumatoid arthritis patients

2014 ◽  
Vol 73 (Suppl 1) ◽  
pp. A20.1-A20
Author(s):  
Fanny Arnoux ◽  
Nathalie Lambert ◽  
Marielle Martin ◽  
Sami B. Kanaan ◽  
Nathalie Balandraud ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF)

2009 ◽  
Vol 52 (8) ◽  
pp. 2255-2264 ◽  
Author(s):  
Dan Niculescu-Duvaz ◽  
Catherine Gaulon ◽  
Harmen P. Dijkstra ◽  
Ion Niculescu-Duvaz ◽  
Alfonso Zambon ◽  
...  
Keyword(s):  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

scholarly journals Corrections to Pyridoimidazolones as Novel Potent Inhibitors of v-Raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF)

2009 ◽  
Vol 52 (18) ◽  
pp. 5770-5770
Author(s):  
Dan Niculescu-Duvaz ◽  
Catherine Gaulon ◽  
Harmen P. Dijkstra ◽  
Ion Niculescu-Duvaz ◽  
Alfonso Zambon ◽  
...  
Keyword(s):  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

Development of Novel, Highly Potent Inhibitors of V-RAF Murine Sarcoma Viral Oncogene Homologue B1 (BRAF): Increasing Cellular Potency through Optimization of a Distal Heteroaromatic Group

2010 ◽  
Vol 53 (7) ◽  
pp. 2741-2756 ◽  
Author(s):  
Bart M. J. M. Suijkerbuijk ◽  
Ion Niculescu-Duvaz ◽  
Catherine Gaulon ◽  
Harmen P. Dijkstra ◽  
Dan Niculescu-Duvaz ◽  
...  
Keyword(s):  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA

2008 ◽  
Vol 68 (4) ◽  
pp. 591-594 ◽  
Author(s):  
I Auger ◽  
N Balandraud ◽  
J Rak ◽  
N Lambert ◽  
M Martin ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Catalytic Domain ◽  
Human Leukocyte ◽  
Arginine Deiminase ◽  
Serum Samples ◽  
Protein Arrays ◽  
Leukocyte Antigen ◽  
Hla Dr ◽  
Oncogene Homologue ◽  
Murine Sarcoma

Objective:To identify new IgG autoantibodies in sera from patients with rheumatoid arthritis (RA).Methods:We tested serum samples from 19 patients with RA with given human leukocyte antigen (HLA)-DR genotypes, from 7 patients with spondylarthropathy, 2 patients with lupus, 4 patients with systemic sclerosis and 10 healthy individuals on 8268 human protein arrays.Results:We identified four antigens (peptidyl arginine deiminase 4 (PAD4), protein kinase Cβ1 (PKCβ1), phosphatylinositol 4 phosphate 5 kinase type II γ (PIP4K2C) and v raf murine sarcoma viral oncogene homologue B1 catalytic domain (BRAF)) that were recognised almost uniquely by sera from patients with RA on protein arrays. Using purified proteins, we confirmed that PAD4 and BRAF are recognised almost uniquely by patients with RA.Conclusion:We identified PAD4 and BRAF as RA specific autoantigens.

Novel Inhibitors of the v-raf Murine Sarcoma Viral Oncogene Homologue B1 (BRAF) Based on a 2,6-Disubstituted Pyrazine Scaffold

2008 ◽  
Vol 51 (11) ◽  
pp. 3261-3274 ◽  
Author(s):  
Ion Niculescu-Duvaz ◽  
Esteban Roman ◽  
Steven R. Whittaker ◽  
Frank Friedlos ◽  
Ruth Kirk ◽  
...  
Keyword(s):  
Viral Oncogene ◽  
Oncogene Homologue ◽  
Murine Sarcoma

scholarly journals Treatment of NRAS-mutated advanced or metastatic melanoma: rationale, current trials and evidence to date

2017 ◽  
Vol 9 (7) ◽  
pp. 481-492 ◽  
Author(s):  
Amélie Boespflug ◽  
Julie Caramel ◽  
Stephane Dalle ◽  
Luc Thomas
Keyword(s):  
Metastatic Melanoma ◽  
Cytotoxic Chemotherapy ◽  
Disease Course ◽  
Line Treatment ◽  
First Line ◽  
Viral Oncogene ◽  
Melanoma Patients ◽  
Murine Sarcoma ◽  
Review Current ◽  
Viral Oncogene Homolog

The disease course of BRAF (v-raf murine sarcoma viral oncogene homolog B1)-mutant melanoma has been drastically improved by the arrival of targeted therapies. NRAS (neuroblastoma RAS viral oncogene homolog)-mutated melanoma represents 15–25% of all metastatic melanoma patients. It currently does not have an approved targeted therapy. Metastatic patients receive immune-based therapies as first-line treatments, then cytotoxic chemotherapy like carboplatin/paclitaxel (C/P), dacarbazine (DTIC) or temozolomide (TMZ) as a second-line treatment. We will review current preclinical and clinical developments in NRAS-mutated melanoma, and analyze ongoing clinical trials that are evaluating the benefit of different targeted and immune-based therapies, either tested as single agents or in combination, in NRAS-mutant melanoma.

Sign in / Sign up

Export Citation Format

Share Document